The Europe Sciatica Treatment Market would witness market growth of 3.1% CAGR during the forecast period (2022-2028).
Sciatica produces tingling, numbness, and a burning feeling that radiates from the lower back and upper buttocks down the back of the hamstring to the back of the foot. Leg discomfort, hip pain, buttock pain, and lumbar pain are the effects of this. There are times when the discomfort extends around the hips or buttocks, feeling something comparable to a hip ache. Walking difficulties might result from severe sciatica.
Surgery is indicated if the discomfort lasts longer than three months. The underlying reasons for sciatica are therapy's main focus, leading to quicker pain alleviation and recovery. The therapy process makes little or no use of electromagnetic waves or medications. As a result, this kind of therapy has no adverse effects on the body. Stress and muscular trigger points are relieved during sciatica therapy. It may trigger the body's innate healing process all over. The patient may avoid spinal surgery as a result. Also, it significantly lessens muscular strains and ligament sprains.
In England, half of the individuals (or 63% of adults) who are overweight or obese will be living there by 2020. As they graduate from elementary school, one in three kids is already overweight or obese, and one in five of them do. The most disadvantaged segments of society have the greatest rates of obesity. According to comparable international figures on overweight and obesity from 2008 (1), 60.5% of adults in Germany (> 20 years old) were heavy, and 25.1% were obese. Men (66.8%) were more likely than women (54.5%) to be overweight. It is anticipated that the rising incidence of obesity and overweight would increase the risk of sciatica. The sciatica treatment market is expected to increase in Europe because of all these reasons.
The Germany market dominated the Europe Sciatica Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $55,234.7 Thousands by 2028. The UK market is anticipated to grow a CAGR of 2.3% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 3.9% during (2022 - 2028).
Based on Type, the market is segmented into Chronic, Acute and Others. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies and Online Providers. Based on Drug Class, the market is segmented into Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Based on End User, the market is segmented into Hospitals, Prosthetic Clinics, Rehabilitation Centers and Others. Based on Type, the market is segmented into Passive, Active and Hybrid. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Sciatica Treatment Market will Hit $810.4 Million by 2028, at a CAGR of 3.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
By Type
By Distribution Channel
By Drug Class
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
